Cargando…
Novel MUC1 Aptamer Selectively Delivers Cytotoxic Agent to Cancer Cells In Vitro
Chemotherapy is a primary treatment for cancer, but its efficacy is often limited by the adverse effects of cytotoxic agents. Targeted drug delivery may reduce the non-specific toxicity of chemotherapy by selectively directing anticancer drugs to tumor cells. MUC1 protein is an attractive target for...
Autores principales: | Hu, Yan, Duan, Jinhong, Zhan, Qimin, Wang, Fengdan, Lu, Xin, Yang, Xian-Da |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284512/ https://www.ncbi.nlm.nih.gov/pubmed/22384115 http://dx.doi.org/10.1371/journal.pone.0031970 |
Ejemplares similares
-
Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting
por: Li, Zhaoyi, et al.
Publicado: (2019) -
Novel Aptamer-Nanoparticle Bioconjugates Enhances Delivery of Anticancer Drug to MUC1-Positive Cancer Cells In Vitro
por: Yu, Chenchen, et al.
Publicado: (2011) -
Aptamer-guided DNA tetrahedron as a novel targeted drug delivery system for MUC1-expressing breast cancer cells in vitro
por: Dai, Bindong, et al.
Publicado: (2016) -
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro
por: Liu, Zhe, et al.
Publicado: (2012) -
Selection of a Novel DNA Aptamer for Assay of Intracellular Interferon-Gamma
por: Cao, Beibei, et al.
Publicado: (2014)